Measurement of health-related quality of life during chemotherapy – the importance of timing
Open Access
- 24 January 2017
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 56 (5), 737-745
- https://doi.org/10.1080/0284186x.2017.1279748
Abstract
Background: Side effects of chemotherapy may occur at different time-points in the treatment cycle, and the exact assessment time relative to chemotherapy may affect HRQoL scores. The current study examined the variation of HRQoL during chemotherapy cycles, and whether differences in HRQoL scores varied at selected time-points between patients allocated to two different chemotherapy regimens. Material and methods: Patients with stage IIIB or IV non-small-cell lung cancer (NSCLC) were randomly assigned to receive three cycles of carboplatin plus vinorelbine (VC) or gemcitabine (GC) every 3 weeks. HRQoL was reported on the EORTC QLQ-C30 and LC13 on days 1, 4, 8, 11 and 15 of every cycle. Global health status, nausea/vomiting, fatigue and dyspnea (LC13) were defined as the HRQoL scales of primary interest. Results: Fifty-two patients were enrolled. Variation of mean scores of global health status, nausea/vomiting and fatigue showed a consistent pattern during chemotherapy. Day 4 appeared to be the time-point when chemotherapy influenced HRQoL the most. The differences in mean HRQoL scores between the two treatment arms varied at the different time-points, especially for nausea/vomiting. Conclusion: There was a clinically relevant variation of HRQoL during chemotherapy cycles, with increased symptom burden the first week following treatment. Our results suggest that timing of HRQoL assessment can influence the chances of detecting differences between the treatment regimens.Keywords
This publication has 21 references indexed in Scilit:
- Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burdenBMC Cancer, 2014
- Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patientsAnnals Of Oncology, 2012
- Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study GroupBritish Journal of Cancer, 2012
- Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trialsCancer Treatment Reviews, 2012
- Health-Related Quality of Life in Non–Small-Cell Lung Cancer: An Update of a Systematic Review on Methodologic Issues in Randomized Controlled TrialsJournal of Clinical Oncology, 2011
- Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTGExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer GroupJournal of Clinical Oncology, 2005
- The Cancer Patient and Quality of LifeThe Oncologist, 2002
- MRC quality of life studies using a daily diary card—practical lessons learned from cancer trialsQuality of Life Research, 1995